Health · 2 views
Another Win for Novel Drug, This Time in EGFR-Mutated Lung Cancer
(MedPage Today) -- A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who…
Summary
(MedPage Today) -- A first-in-class bispecific antibody-drug conjugate (ADC) nearly doubled progression-free survival (PFS) compared with chemotherapy in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on third
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- New microscopy platform enables imaging of neuronal activity at single-cell resolution at unprecedented tissue depthContinue reading
- Lab-on-a-chip predicts which cancer treatments may work for pediatric acute lymphoblastic leukemiaContinue reading
- Nearly 75% of ex-NFL players who died from 2008-2023 had CTE, study findsContinue reading
- Couples Achieved Live Births Faster With IVF FirstContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow